百诚医药：控股股东拟增持5000万元至1亿元

Core Viewpoint - The controlling shareholder of Baicheng Pharmaceutical (301096), Lou Jinfang, plans to increase his stake in the company by investing between 50 million and 100 million yuan within six months, with a maximum purchase price of 60 yuan per share [1] Group 1 - The planned share buyback will not exceed 2.00% of the company's total share capital [1] - The funding for the share purchase will come from personal or self-raised funds [1] - The implementation of the buyback plan may face risks due to changes in the capital market, which could affect the expected outcomes [1]